iRadimed/$IRMD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About iRadimed
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
Ticker
$IRMD
Sector
Primary listing
Employees
160
Headquarters
Website
iRadimed Metrics
BasicAdvanced
$977M
47.71
$1.61
0.95
$0.66
0.89%
Price and volume
Market cap
$977M
Beta
0.95
52-week high
$80.65
52-week low
$47.48
Average daily volume
60K
Dividend rate
$0.66
Financial strength
Current ratio
8.778
Quick ratio
6.012
Dividend payout ratio (TTM)
39.33%
Profitability
EBITDA (TTM)
24.603
Gross margin (TTM)
76.96%
Net profit margin (TTM)
26.61%
Operating margin (TTM)
30.67%
Effective tax rate (TTM)
20.66%
Revenue per employee (TTM)
$490,000
Management effectiveness
Return on assets (TTM)
15.15%
Return on equity (TTM)
23.75%
Valuation
Price to earnings (TTM)
47.713
Price to revenue (TTM)
12.561
Price to book
10.36
Price to tangible book (TTM)
10.36
Price to free cash flow (TTM)
73.146
Free cash flow yield (TTM)
1.37%
Free cash flow per share (TTM)
1.05
Dividend yield (TTM)
0.86%
Forward dividend yield
0.89%
Growth
Revenue change (TTM)
11.73%
Earnings per share change (TTM)
10.28%
3-year revenue growth (CAGR)
17.54%
10-year revenue growth (CAGR)
13.55%
3-year earnings per share growth (CAGR)
18.85%
10-year earnings per share growth (CAGR)
17.50%
What the Analysts think about iRadimed
Analyst ratings (Buy, Hold, Sell) for iRadimed stock.
Bulls say / Bears say
Reported record Q2 2025 revenue of $20.4 million, a 14% year-over-year increase, alongside GAAP diluted EPS of $0.45 (up 18%), and raised full-year 2025 revenue and earnings guidance, highlighting robust operational momentum (Nasdaq)
Received FDA 510(k) clearance on May 29, 2025 for its next-generation MRidium® 3870 IV Infusion Pump System, reinforcing its exclusive position as the sole supplier of non-magnetic MRI-compatible infusion pumps (SEC)
Declared a regular quarterly cash dividend of $0.17 per share for Q3 2025 in its Q2 release, underscoring a commitment to shareholder returns and financial discipline (Nasdaq)
Exposed to potential cost increases from global trade tensions, IRadimed is monitoring tariff changes and implementing mitigation plans, but persistent tariff risks could erode margins if global trade policies worsen (SEC)
Manufacturing is concentrated at a single facility in Florida; any disruption from natural disasters or other events could halt production and materially impact revenue and operating results (SEC)
Domestic sales comprised 82% of total revenue in Q1 2025, up from 76% in the prior year, reflecting a reliance on the U.S. market and limited international diversification, which could expose the company to regional market downturns (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2025.
iRadimed Financial Performance
Revenues and expenses
iRadimed Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for iRadimed stock?
iRadimed (IRMD) has a market cap of $977M as of November 02, 2025.
What is the P/E ratio for iRadimed stock?
The price to earnings (P/E) ratio for iRadimed (IRMD) stock is 47.71 as of November 02, 2025.
Does iRadimed stock pay dividends?
Yes, the iRadimed (IRMD) stock pays dividends to shareholders. As of November 02, 2025, the dividend rate is $0.66 and the yield is 0.89%. iRadimed has a payout ratio of 39.33% on a trailing twelve-month basis.
When is the next iRadimed dividend payment date?
The next iRadimed (IRMD) dividend payment date is unconfirmed.
What is the beta indicator for iRadimed?
iRadimed (IRMD) has a beta rating of 0.95. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.